Medication info
Glotinduo Tablet 2.5/1000mg (Linagliptin, Metformin Hydrochloride)

Glotinduo Tablet 2.5/1000mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Nexpam Korea Co., Ltd.
Appearance
Bright pink, biconvex, oval film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP x 5)]
Approval status
Active

MFDS item code 202001276 · Approved 2020.02.21 · Insurance code 662504590

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. Dose increases should be made gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no history of previous antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not Administer to the Following Patients).

Ingredients

Manufacturer
Nexpam Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication assists in dietary and exercise therapy in patients with type 2 diabetes and significantly improves blood glucose control when taken with Linagliptin and Metformin.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. Dose increases should be made gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no history of previous antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not Administer to the Following Patients).

Precautions

This medication is a blood glucose control aid, especially for patients with type 2 diabetes. It should not be administered to patients with impaired kidney function, and kidney function should be regularly checked to ensure it is normal. Lactic acidosis, which is a serious side effect, may rarely occur, so if symptoms such as abdominal pain, muscle pain, weakness, or difficulty breathing occur, consult a doctor immediately. This medication should not be administered to patients with liver dysfunction or those with acute heart failure or acute myocardial infarction. It is advisable not to use this medication in pregnant women or women of childbearing potential, as well as nursing mothers. Due to the risk of hypoglycemia, blood glucose levels should be closely monitored when used in conjunction with sulfonylureas or insulin. Some patients may experience allergic reactions such as pancreatitis or bullous rashes, so if severe abdominal pain or skin abnormalities occur, notify healthcare providers immediately. Prolonged use may decrease vitamin B12 levels, so vitamin B12 testing should be done if necessary. There may be interactions with other medications, so if taking other medicines, it is essential to inform a doctor or pharmacist. This medication should be temporarily discontinued before surgery or radiological examinations and resumed after kidney function recovers. Elderly patients may have reduced kidney function; therefore, dose adjustments and regular kidney function checks are necessary. It is not recommended for children and adolescents as safety and efficacy have not been established.

Side effects

Lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, formation of oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, blistering pemphigoid, arthralgia associated with severe and disability, rhabdomyolysis, increased lipase, increased amylase, stomatitis, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, hearing loss, dizziness, erectile dysfunction, goiter, kidney transplant failure, anemia, headache, sensory disturbances, postherpetic neuralgia, hemiparesis, syncope, drowsiness, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disorder, epistaxis, male pattern hair loss, hyperhidrosis, hair loss, dermatitis, anxiety, affective disorder, insomnia, depression, hypertension, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, diarrhea, pancreatitis, stomatitis, mediastinitis, pneumonia, rhinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, stomatitis, dizziness, diabetic neuropathy, subdural effusion, palpitations, confusional state, nocturia, pruritus, hyperglycemia, increased blood creatinine, facial edema, hyperthermia, back pain, rotator cuff syndrome, corneal abrasion, falls, upper limb fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. It is essential to maintain the storage temperature between 1°C and 30°C to preserve its effectiveness for a longer period.

Appearance and packaging

Appearance

Bright pink, biconvex, oval film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP x 5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.